Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1151.08
ACHN's Cash to Debt is ranked higher than
76% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ACHN: 1151.08 )
ACHN' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1151.08

F-Score: 3
Z-Score: 72.87
M-Score: -4.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -43.31
ACHN's ROE (%) is ranked higher than
71% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. ACHN: -43.31 )
ACHN' s 10-Year ROE (%) Range
Min: -199.15   Max: -52.4
Current: -43.31

-199.15
-52.4
ROA (%) -40.39
ACHN's ROA (%) is ranked higher than
68% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. ACHN: -40.39 )
ACHN' s 10-Year ROA (%) Range
Min: -181.02   Max: -48.33
Current: -40.39

-181.02
-48.33
ROC (Joel Greenblatt) (%) -4570.28
ACHN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. ACHN: -4570.28 )
ACHN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6066.62   Max: -465.75
Current: -4570.28

-6066.62
-465.75
Revenue Growth (3Y)(%) -100.00
ACHN's Revenue Growth (3Y)(%) is ranked higher than
52% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ACHN: -100.00 )
ACHN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -42.3
Current: -100

EBITDA Growth (3Y)(%) 4.10
ACHN's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ACHN: 4.10 )
ACHN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 4.1
Current: 4.1

0
4.1
EPS Growth (3Y)(%) 3.40
ACHN's EPS Growth (3Y)(%) is ranked higher than
82% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ACHN: 3.40 )
ACHN' s 10-Year EPS Growth (3Y)(%) Range
Min: -65.5   Max: 3.4
Current: 3.4

-65.5
3.4
» ACHN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ACHN Guru Trades in Q4 2013

Chuck Royce 590,000 sh (New)
Paul Tudor Jones 48,767 sh (New)
Jean-Marie Eveillard 600,000 sh (New)
Steven Cohen Sold Out
» More
Q1 2014

ACHN Guru Trades in Q1 2014

Steven Cohen 43,533 sh (New)
Jean-Marie Eveillard Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 500,000 sh (-15.25%)
» More
Q2 2014

ACHN Guru Trades in Q2 2014

Paul Tudor Jones 26,592 sh (New)
Steven Cohen 547,200 sh (unchged)
Chuck Royce 2,262 sh (-99.55%)
» More
Q3 2014

ACHN Guru Trades in Q3 2014

Jim Simons 897,300 sh (New)
Steven Cohen 1,048,100 sh (+91.54%)
Paul Tudor Jones 45,217 sh (+70.04%)
Chuck Royce 2,262 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ACHN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.01%$3.08 - $4.2 $ 14.21306%0
Jean-Marie Eveillard 2013-12-31 New Buy0.01%$2.43 - $3.46 $ 14.21390%600000
John Burbank 2012-12-31 Sold Out 0.24%$7.2 - $11.1 $ 14.2160%0
John Burbank 2012-09-30 New Buy0.24%$5.61 - $10.41 $ 14.21101%500000
George Soros 2012-06-30 Sold Out 0.04%$5.94 - $10.95 $ 14.2194%0
George Soros 2012-03-31 Reduce -50%0.09%$7.71 - $12.375 $ 14.2148%250000
George Soros 2011-12-31 Add 2132.14%0.16%$4.01 - $8 $ 14.21131%500000
George Soros 2011-09-30 New Buy$4.63 - $8.31 $ 14.21123%22400
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.94
ACHN's P/B is ranked higher than
64% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. ACHN: 11.94 )
ACHN' s 10-Year P/B Range
Min: 0.79   Max: 16.46
Current: 11.94

0.79
16.46
EV-to-EBIT -21.05
ACHN's EV-to-EBIT is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ACHN: -21.05 )
ACHN' s 10-Year EV-to-EBIT Range
Min: -23.5   Max: 0.6
Current: -21.05

-23.5
0.6
Current Ratio 11.73
ACHN's Current Ratio is ranked higher than
89% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ACHN: 11.73 )
ACHN' s 10-Year Current Ratio Range
Min: 1.06   Max: 14.96
Current: 11.73

1.06
14.96
Quick Ratio 11.73
ACHN's Quick Ratio is ranked higher than
90% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ACHN: 11.73 )
ACHN' s 10-Year Quick Ratio Range
Min: 1.06   Max: 14.96
Current: 11.73

1.06
14.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.36
ACHN's Price/Net Cash is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. ACHN: 12.36 )
ACHN' s 10-Year Price/Net Cash Range
Min: 0.82   Max: 12.7
Current: 12.36

0.82
12.7
Price/Net Current Asset Value 12.36
ACHN's Price/Net Current Asset Value is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. ACHN: 12.36 )
ACHN' s 10-Year Price/Net Current Asset Value Range
Min: 0.82   Max: 12.7
Current: 12.36

0.82
12.7
Price/Tangible Book 11.94
ACHN's Price/Tangible Book is ranked higher than
69% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. ACHN: 11.94 )
ACHN' s 10-Year Price/Tangible Book Range
Min: 0.72   Max: 77.75
Current: 11.94

0.72
77.75
Earnings Yield (Greenblatt) -4.80
ACHN's Earnings Yield (Greenblatt) is ranked higher than
76% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ACHN: -4.80 )
ACHN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 176.4   Max: 2710.2
Current: -4.8

176.4
2710.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ADA.Germany,
Achillion Pharmaceuticals Inc was incorporated on August 17, 1998 in Delaware. The Company is a biopharmaceutical company which focuses on the discoveries, develops and commercializes treatments for infectious diseases. Within the anti-infective market, it is currently focusing its efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C infection that are administered once-daily, orally, and without ribavirin. The Company competes with Abbvie, Astra-Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Enanta, Gilead, GlaxoSmithKline, Idenix, Johnson & Johnson, Presidio, Medivir, Merck, Novartis, Pfizer, Roche, Valeant and Vertex. The Company's drug candidates is subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, record keeping, labeling, marketing and distribution of drugs.
» More Articles for ACHN

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
comment on ACHN Mar 15 2013 
comment on ACHN Mar 09 2013 
Achillion Will Surge If New Drug Is Successful Apr 21 2012 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 03 2009 

More From Other Websites
Nasdaq stocks posting largest percentage increases Dec 19 2014
Six Biotech and Technology Stocks With Strong Technical Set-Ups Dec 18 2014
These 4 Biotech Stocks Have Been On Fire Dec 08 2014
5 Stock-Moving Medtech Events This December Nov 28 2014
Achillion to Present at Two Upcoming Investor Conferences Nov 25 2014
Achillion to Present at Two Upcoming Investor Conferences Nov 25 2014
Deutsche Bank Mystified By 18% Jump In Achillion Pharmaceuticals Nov 13 2014
Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? Nov 13 2014
Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results Nov 12 2014
Achillion Jumps on Encouraging Data on its HCV Candidate Nov 11 2014
ACHILLION PHARMACEUTICALS INC Financials Nov 11 2014
AbbVie, Enanta drug shows potential in hep C genotype 4 patients Nov 11 2014
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% Nov 11 2014
Achillion rises on new hepatitis C drug study Nov 10 2014
Achillion rises on new hepatitis C drug study Nov 10 2014
Merck Down On Hepatitis C Data; Gilead Rises Nov 10 2014
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting Nov 10 2014
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014... Nov 08 2014
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014... Nov 08 2014
Stocks to watch ahead of liver disease conference Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK